CABERDOST 0.5 Tablet is a therapeutically significant product containing Cabergoline, a potent long-acting dopamine receptor agonist. Cabergoline specifically targets dopamine D2 receptors in the pituitary gland, where it acts to inhibit the secretion of prolactin. Elevated prolactin levels can result in various clinical complications, including menstrual irregularities, infertility, galactorrhea (abnormal breast milk production), sexual dysfunction, and bone demineralization. CABERDOST 0.5 Tablet effectively reduces serum prolactin concentrations, thereby normalizing endocrine function and relieving associated symptoms.
Cabergoline is widely used in the treatment of hyperprolactinemia, whether idiopathic or due to pituitary adenomas (prolactinomas). In many patients, treatment with Cabergoline helps restore ovulatory cycles, improve fertility outcomes, and reduce tumor size. It is often preferred over other dopamine agonists like bromocriptine due to its longer half-life, improved tolerability, and once or twice weekly dosing schedule. This improved dosing frequency enhances patient adherence, especially in chronic treatment protocols.
CABERDOST 0.5 is particularly effective for patients with microadenomas and macroadenomas of the pituitary gland. Studies have shown that Cabergoline can reduce prolactin levels in more than 90% of cases and lead to significant tumor shrinkage in up to 70% of patients with macroprolactinomas. It is the first-line pharmacologic treatment in most international clinical guidelines for hyperprolactinemia.
The pharmacodynamic profile of Cabergoline in CABERDOST 0.5 reveals that it acts by mimicking the effects of dopamine on the pituitary lactotroph cells. The inhibition of prolactin release occurs within 3 hours of oral ingestion, and the effect can last for up to 1–2 weeks. This duration is due to Cabergoline’s long elimination half-life, which ranges from 63 to 115 hours depending on the individual’s metabolic rate. Such a pharmacokinetic advantage allows for less frequent dosing—typically twice weekly, as opposed to daily dosing required with older medications.
The pharmacokinetics of CABERDOST 0.5 Tablet demonstrate excellent oral absorption with high bioavailability. Food intake does not significantly affect absorption, although taking the tablet with food can improve gastrointestinal tolerability. The compound is extensively metabolized in the liver via hydrolysis of the acylurea bond and minimal CYP450 involvement, minimizing the potential for major drug interactions. It is excreted primarily via feces, with a smaller amount eliminated in urine.
Description provided by bluepill express.
FIEO Registered
Export Ready
